Public Support for COVID-19 Test Allocation
7. januar 2022 opdateret af: Alison Buttenheim, University of Pennsylvania
Race, Status, Vaccines, Tests, and Place: Public Attitudes and Support for Equitable COVID-19 Vaccine and Test Allocation
In a randomized survey experiment, investigators will assess public support or opposition towards one of three potential government plans for allocating at-home coronavirus disease 2019 (COVID-19) tests to United States residents: 1) first come, first served; 2) a random draw; or 3) a random draw with 20% of tests reserved for disadvantaged areas.
Investigators will also examine public attitudes surrounding other logistical and equity-related aspects of these allocation plans.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Complementing other efforts to increase access to COVID-19 testing in the United States, the federal government recently announced the purchase of 500,000,000 at home COVID-19 to be distributed for free "to Americans that want them".
A central logistical element in matching supply with demand will be a website, on which people will register their interest in getting tests delivered to their home address.
However, it is still unclear how supply will be matched with demand.
Three main candidate options are first come, first served (FCFS), in which people are sent tests in the order in which they make requests; a random draw, such as a lottery; or a combination of a random draw with a guaranteed reserved amount for more disadvantaged populations.
FCFS is a widely known and practiced rationing principle, but it has shown to exacerbate inequities in, for example, the allocation of vaccine appointments.
Random draws can mitigate this impact, but, in the present context, might be insufficiently sensitive to the fact that not everyone has internet access, and that the need for testing is greater among more disadvantaged communities.
Combining a lottery with a disadvantage reserve system using measures such as the CDC's Social Vulnerability Index is a practical way of promoting equity, and it was already used by the majority of US states in allocating vaccines.
The main objective of this study is to assess public support for each of these three allocation plans and describe differences by demographic characteristics.
Investigators will also assess public attitudes toward specific details of these allocation plans.
The study, which is expected to take approximately 5 minutes to complete, will be administered as part of an omnibus online survey.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
2019
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
District of Columbia
-
Washington, District of Columbia, Forenede Stater, 20006
- Harris Insights & Analytics
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ja
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Aged 18 years old or older, United States resident
Exclusion Criteria:
- None
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Sundhedstjenesteforskning
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: First Come, First Served
Respondents will view the following description: "The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:" Below this statement, respondents will view the "First Come, First Served" plan description. |
Respondents will view the following description of the plan: "Tests will be sent out in the order they are requested.
People who request tests the quickest will get them first, no matter where they live.
People who request tests later may not get any.
This strategy is also known as 'First Come, First Served.'"
|
|
Eksperimentel: Random
Respondents will view the following description: "The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:" Below this statement, respondents will view the "Random" plan description. |
Respondents will view the following description of the plan: "People who request tests will be entered into a random drawing, like a sweepstakes or lottery.
Everyone who is in the drawing has the same chance of getting tests, no matter where they live, but some people may not get any tests."
|
|
Eksperimentel: Disadvantaged Priority & Random
Respondents will view the following description: "The US government will make 500 million COVID-19 home tests available for free. US residents can ask for tests by entering their home address in a website. It is likely that more people will want tests than will be available. How should the government decide who will receive tests, when there are not enough for all who want them? One plan that is being considered is this one:" Below this statement, respondents will view the "Disadvantaged Priority & Random" plan description. |
Respondents will view the following description of the plan: "Because COVID-19 has hit people living in disadvantaged areas of the country harder, a proportion of tests will be sent exclusively to people in these zip codes.
Planners will allocate 80% of the tests using a random drawing, like a sweepstakes or lottery.
Everyone who is in the drawing has the same chance of getting tests, no matter where they live.
The remaining 20% are set aside exclusively for the most disadvantaged areas, again allocated with a random drawing.
Some people may not get any tests.
But people living in disadvantaged areas are more likely to get them."
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Support for allocation plan
Tidsramme: 5 minutes
|
Self-reported degree of support for the plan, measured on a 5-point Likert scale ("strongly oppose" to "strongly support") that will be collapsed into 3 response categories ("oppose," "neutral," and "support") for analysis.
|
5 minutes
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Household-level test allocation preference
Tidsramme: 5 minutes
|
Preferred way of sending tests to households, measured as a binary choice between a fixed or variable (based on household size) number of tests per household.
|
5 minutes
|
|
Tests allocated to disadvantaged areas
Tidsramme: 5 minutes
|
Self-reported percentage of tests wanted to be sent to disadvantaged areas, measured as a continuous variable on a slider from 0% to 100% with increments of 0.1%.
This outcome will only be measured for respondents in the "Disadvantaged Priority & Random" condition.
|
5 minutes
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Alison M Buttenheim, PhD, MBA, University of Pennsylvania
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
4. januar 2022
Primær færdiggørelse (Faktiske)
6. januar 2022
Studieafslutning (Faktiske)
6. januar 2022
Datoer for studieregistrering
Først indsendt
7. januar 2022
Først indsendt, der opfyldte QC-kriterier
7. januar 2022
Først opslået (Faktiske)
11. januar 2022
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
11. januar 2022
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
7. januar 2022
Sidst verificeret
1. januar 2022
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 848725
- #84525 (Registry Identifier: AsPredicted)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
UBESLUTET
IPD-planbeskrivelse
Only de-identified individual participant data will be shared by Harris Insights & Analytics to the research team.
Each participant will have a unique identifier to protect their confidentiality.
Only authorized research personnel will have access to the data which will be maintained on encrypted hard-drives.
Individual participant data may be made available to other researchers in an open-access repository.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .